hearing evaluation in oropharyngeal cancer patients

EVALUATION OF HEARING LOSS IN LOCALLY ADVANCED OROPHARYNGEAL CANCER PATIENTS TREATED WITH RADICAL CHEMORADIOTHERAPY

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/02/017526

Enrollment

Registered

2019-02-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C109- Malignant neoplasm of oropharynx,unspecified Health Condition 2: null- oropharyngeal cancers

Interventions

Intervention1: EBRT CONCURRENT CHEMOTHERAPY with IMRT: Comparison of hearing loss in oropharyngeal cancel patients receiving chemoradiation by two different radiation delivery modalities Control Inte

Eligibility

Inclusion criteria

Inclusion criteria: •Histo pathologically proven oropharyngeal cancers. •Karnofsky performance status above 70 •Stage III-IVB carcinoma oropharynx planned for curative treatments. •Patients willing for informed consent and regular follow up •No previous history of hearing loss

Exclusion criteria

Exclusion criteria: •Patients who have received previous chemoradiotherapy. •Patients with significant pre-existing congenital or acquired hearing loss. •Patient co- morbid conditions like hypertension, diabetes or any renal impairment.

Design outcomes

Primary

Measure	Time frame
Evaluation of hearing evaluationTimepoint: Evaluation of hearing status at 6 weeks ,3 months and 6 months of completion of radiation therapy	—

Secondary

Measure	Time frame
Local controlTimepoint: 6 months	—

Countries

India

Contacts

Public ContactDr Lokeswari

POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH

dramitbahl@yahoo.com8195990813

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026